<DOC>
	<DOC>NCT01235351</DOC>
	<brief_summary>To determine whether higher as compared with lower maintenance doses of clopidogrel can adequately improve the degree of platelet inhibition in carriers of a reduced-function CYP2C19 allele.</brief_summary>
	<brief_title>Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Inclusion Criteria (major): 1. Between 18 and 75 years of age, inclusive. 2. Have an indication for the use of clopidogrel defined as either spontaneous MI [hospitalized with final diagnosis of MI, excluding periprocedural or definite secondary MI (e.g., due to anemia or hypertensive emergency)] or PCI within the past 6 months. 3. Clinically stable and at least 4 weeks following the MI or PCI. Exclusion Criteria (major): 1. Conditions that alter platelet function. 2. Conditions that increase bleeding risk.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Myocardial infarction</keyword>
	<keyword>Percutaneous coronary intervention</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>Genetics</keyword>
	<keyword>Platelet Function</keyword>
</DOC>